Pharmaceuticals firm Wockhardt announced Q3FY23 results: Q3FY23: UK business stood at Rs 223 crore in Q3FY23. UK business contributed about 32% of global revenue. India Business stood at Rs 175 crore compared to Rs 158 crore in Q3FY22, registering a growth of 11%. India Business contributed 25% of the global revenue. Emerging markets business of the company stood at Rs 148 crore in Q3FY23 compared to Rs 117 crore in Q2FY23, registering a growth of 27%. Emerging markets business contributed about 21% of the global revenue. Irish business stood at Rs 40 crore in Q3FY23 compared to Rs 38 crore in Q2FY23, showing a growth of 4%. US business stood at Rs 91 crore in Q3FY23. US business contributed 13% of the global revenue. Research and development expenditure during the quarter was at Rs 40 crore (6% to sales) and including capital expenditure was at 10.3% to sales. 9MFY23: UK business stood at Rs 645 crore in 9MFY23. UK business contributed about 33% of global revenue. India business stood at Rs 483 crore. India business contributed 25% of the global revenue. Emerging markets business of the company stood at Rs 382 crore in 9MFY23. Emerging markets business contributed about 19% of the global revenue. Irish business stood at Rs 115 crore in 9MFY23. US business stood at Rs 253 crore in 9MFY23. US business contributed 13% of the global revenue. Research and development expenditure during the period was at Rs 115 crore (6% to sales) and including capital expenditure was at 10.9% to sales. Result PDF
Pharmaceutical company Wockhardt announced Q2FY23 results: The Company recorded a Revenue of Rs.679 crore in Q2FY23 compared to Rs.595 crore in the previous quarter registering a growth of 14%. EBITDA for the quarter is Rs.43 crore as compared to Rs. (16) crore in Q1FY23 registering a substantial growth of 369%. Q2FY23 Global revenue: UK Business stood at Rs.226 crore in Q2FY23 (PY Rs.387 Cr). UK Business contributed about 33% of Global Revenue. India Business: India Business stood at Rs.150 crore (PY Rs.187 crore). India's Business contributed 22% of the Global Revenue. EMROK, the NCE launched during FY21 continues to provide unmatched benefits to patients. The emerging Markets Business of the Company stood at Rs.117 crore in Q2FY23 (PY Rs.165 Cr). Emerging Markets Business contributed about 17% of the Global Revenue. Irish Business stood flat at Rs.38 crore in Q2FY23 compared to the previous year. US Business stood at Rs.89 crore in Q2FY23 compared to Rs.61 crore in the previous year registering a growth of 45%. US Business contributed 13% of the Global Revenue. US business was impacted by price erosion and supply disruptions. Research and Development expenditure during the quarter was at Rs.39 crore (6% to sales) and including capital expenditure was at 11.8% to sales. Result PDF